A common practice for treating patients with gastrointestinal conditions has been revised by the American Gastroenterological Association, it announced Feb. 21. The group has expanded its ...

In the first comprehensive evidence-based guideline on the use of fecal microbiota-based therapies for gastrointestinal disease, the American Gastroenterological Association recommends fecal ...

Other new treatment recommendations include: Vancomycin or fidaxomicin – Antibiotics vancomycin or fidaxomicin should be used for initial treatment of even mild C. diff., rather than metronidazole, ...

C. diff is a horrible disease that can cause significant morbidity. It can and often does recur and kills around 30,000 Americans every year. We have made progress in prevention and treatment, but ...

Arlington, Va. — June 27, 2024 — A new study published today in the American Journal of Infection Control (AJIC) describes the outcome of a new approach to testing for Clostridioides difficile (C.

Clostridium difficile treatment in the outpatient setting often deviates from guidelines, according to a Medscape report. A team of researchers found both under-treatment and overtreatment of C. diff ...

In the first comprehensive evidence-based guideline on the use of fecal microbiota-based therapies for gastrointestinal disease, the American Gastroenterological Association recommends fecal ...

C. diff is a type of bacteria that can cause diarrhea, abdominal pain, and tenderness. It is commonly treated with antibiotics such as fidaxomicin (Dificid) and vancomycin (Firvanq). C. diff, short ...